APPLIED THERAPEUTICS INC. - COMMON STOCK

Applied Therapeutics Announces $100 Million Private Placement

28 Feb 2024 05:05:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia

28 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency

15 Feb 2024 04:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

04 Jan 2024 13:05:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia

03 Jan 2024 04:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Third Quarter 2023 Financial Results

09 Nov 2023 04:30:54 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the UBS Biopharma Conference 2023

02 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7

01 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting

28 Sep 2023 04:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023

06 Sep 2023 04:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Second Quarter 2023 Financial Results

10 Aug 2023 04:00:44 By Nasdaq GlobeNewswire

Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association

22 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve Society

15 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency

25 May 2023 04:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports First Quarter 2023 Financial Results

11 May 2023 04:00:35 By Nasdaq GlobeNewswire

Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity

24 Apr 2023 04:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission

24 Apr 2023 04:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results

23 Mar 2023 03:30:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

01 Mar 2023 04:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency

16 Feb 2023 04:00:01 By Nasdaq GlobeNewswire